Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic acetylated peptide corresponding to C-terminus of human Vimentin was used as an immunogen.
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
Vimentin is the most common member of intermediate filament (IF) family and one of the main components in cytoskeleton structure. It is expressed during cell development and differentiation in variety of mescencymal cells and cell types derived from mesoderm (1). Vimentin is essential in the role of cell integrity and cytoskeletal stability. The reorganization of Vimentin, similar to all IF proteins, occurs during different stages of the cell cycle and cell signaling by a site-specific phosphorylation (serine and threonine residues) (2). In particular, p21-activated kinase (PAK) phosphorylates at Ser25, Ser38, Ser50, Ser65 and Ser72 which induces Vimentin specific reorganization (3). During cytokinesis, Vimentin is regulated by Rho-kinase (ROCK) and Aurora B through phosphorylation at Ser38 and Ser72 (4). Also, coordinated by ROCK and Aurora B, Plk1 induces phosphorylation at Ser82 plays an important role in Vimentin segregation (5).
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
